14:25 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Several analysts raised their price targets a day after the company reported a 28% quarterly sales increase, helped by a strong performance for the new diabetes drug Mounjaro. Lilly also completed its purchase of DICE Therapeutics, expanding its immunology portfolio. Lilly was up 2%, to $530.09, on Wednesday after rising 15% Tuesday. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)


(END) Dow Jones Newswires

08-09-23 1440ET